Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-20T07:23:20.350Z Has data issue: false hasContentIssue false
  • English
  • Français

Death associated with coronavirus (COVID-19) infection in individuals with severe mental disorders in sweden during the early months of the outbreak

Published online by Cambridge University Press:  13 August 2021

U. Werneke ,
M. Maripuu ,
M. Bendix ,
L. Öhlund  and
M. Widerstrom
U. Werneke*
Affiliation:
Sunderby Research Unit, Umeå University, Deparment of clinical science, division of psychiatry, Umeå, Sweden
M. Maripuu
Affiliation:
Department Of Clinical Sciences- Psychiatry, Umeå University, Umeå, Sweden
M. Bendix
Affiliation:
Department Of Clinical Sciences- Psychiatry, Umeå University, Umeå, Sweden
L. Öhlund
Affiliation:
Sunderby Research Unit, Umeå University, Deparment of clinical science, division of psychiatry, Umeå, Sweden
M. Widerstrom
Affiliation:
Clinical Microbiology, Umeå University, Umeå, Sweden
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Individuals with severe mental disorder (SMD) have a higher risk of somatic comorbidity and mortality than the rest of the population.

Objectives

To assess whether individuals with SMD had a higher risk of death associated with a COVID-19 infection (COVID-19 associated death) than individuals without SMD.

Methods

Exploratory analysis with a cross-sectional design in the framework of a population-based register study covering the entire Swedish population. The Swedish Board for Health and Welfare (Socialstyrelsen) provided anonymised tabulated summary data for further analysis. We compared numbers of COVID-19 associated death in individuals with SMD (cases) and without SMD (controls). We calculated the odds ratio (OR) for the whole sample and by age group and four potential risk factors, namely diabetes, cardiovascular disease, hypertension, chronic lung disease.

Results

The sample comprised of 7,923,859 individuals, 103,999 with SMD and 7,819,860 controls. There were 130 (0.1%) COVID-19 associated deaths in the SMD group and 4945 (0.06%) in the control group, corresponding to an OR of 1.98 (CI 1.66-2.35; p < 0.001). The odds were fourfold in the age group between 60 and 79 years. Cardiovascular diseases increased the odds by 50%. Individuals with SMD without any of the risk factors under study had three-folds odds of COVID-19 associated death.

Conclusions

Our preliminary results suggest that individuals with SMD are a further group at increased risk of COVID-19 associated death. The factors contributing to this increased mortality risk require clarification.

Disclosure

Ursula Werneke has received funding for educational activities on behalf of Norrbotten Region (Masterclass Psychiatry Programme 2014-2018 and EAPM 2016, Luleå, Sweden): Astra Zeneca, Eli Lilly, Janssen, Novartis, Otsuka/Lundbeck, Servier, Shire and Sunovi

Keywords

COVID-19mental disorderMortalitycoronavirus
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S119 - S120
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.